者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688331 证券简称：荣昌生物 公告编号：2025-053 荣昌生物制药（烟台）股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 12 月 2 日 （二） 股东会召开的地点：山东省烟台市经济技术开发区北京中路 58 号荣昌生 物三期 6134 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 180 | | --- | --- | | 普通股股东人数 | 180 | | 其中：A 股股东人数 | 179 | | 境外上市外资股股东人数 | 1 | | 2、出席会议的股东所持有的表决权数量 | 268,223,021 | | 普通股股东所持有表决权数量 | 268,223,021 | | 其中：A 股股东所持有表决权数量 | 236,190,402 | | 境外上 ...

为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 北京市金杜律师事务所 关于荣昌生物制药（烟台）股份有限公司 2025 年第三次临时股东会 之法律意见书 致：荣昌生物制药（烟台）股份有限公司 北京市金杜律师事务所（以下简称本所）接受荣昌生物制药（烟台）股份有限 公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证券法》）、 《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理委员会《上 市公司股东会规则》（以下简称《股东会规则》）等中华人民共和国境内（以下简 称中国境内，为本法律意见书之目的，不包括中国香港特别行政区、中国澳门特别 行政区和中国台湾省）现行有效的法律、行政法规、规章、规范性文件和现行有效 的公司章程的有关规定，指派律师出席了公司于 2025 年 12 月 2 日召开的 2025 年 第三次临时股东会（以下简称"本次股东会"），并就本次股东会相关事项出具本 法律意见书。 5. 2025 年 11 月 14 日，公司刊登于上海证券交易所网站（www.sse.com.cn） 的《荣昌生物制药（烟台）股份有限公司第二届董事会第三十一次会议决议公告》； 6 ...

Market Overview - The biopharmaceutical sector experienced a decline of 1.72% on December 2, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1] Individual Stock Performance - Dongbao Bio (300239) closed at 5.80, up 1.05% with a trading volume of 93,700 shares and a transaction value of 53.99 million yuan [1] - Aopumai (688293) saw a significant drop of 8.01%, closing at 50.32 with a trading volume of 33,400 shares and a transaction value of 171 million yuan [2] - Other notable declines included Kanghong Pharmaceutical (002773) down 3.78% and Watson Bio (300142) down 3.17% [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 456 million yuan from institutional investors, while retail investors saw a net inflow of 270 million yuan [2] - Notable stocks with significant capital inflows included He Yuan Bio (688765) with a net inflow of 17.69 million yuan from institutional investors [3] - Conversely, stocks like Rongchang Bio (688331) and Shenzhou Cell (688520) also saw mixed capital flows, indicating varied investor sentiment [3]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 榮昌生物製藥（煙台）股份有限公司 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09995 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 208,581,239 | RMB | | 1 RMB | | 208,581,239 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 208,581,239 | RMB | | 1 RMB | | 208,581,239 | | 2. 股份分類 | 普通股 | 股份類別 | A ...

荣昌生物今年以来股价涨209.70%，近5个交易日涨6.57%，近20日跌3.61%，近60日跌3.69%。 今年以来荣昌生物已经4次登上龙虎榜，最近一次登上龙虎榜为6月26日，当日龙虎榜净买入-1.37亿 元；买入总计2.35亿元 ，占总成交额比15.86%；卖出总计3.72亿元 ，占总成交额比25.12%。 资料显示，荣昌生物制药(烟台)股份有限公司位于中国(山东)自由贸易试验区烟台片区烟台开发区北京 中路58号，成立日期2008年7月4日，上市日期2022年3月31日，公司主营业务涉及公司是一家具有全球 化视野的创新型生物制药企业,自成立以来一直专注于抗体药物偶联物(ADC)、抗体融合蛋白、单抗及 双抗等治疗性抗体药物领域。公司致力于发现、开发与商业化创新、有特色的同类首创(first-in-class)与 同类最佳(best-in-class)生物药,以创造药物临床价值为导向,为自身免疫疾病、肿瘤疾病、眼科疾病等重 大疾病领域提供安全、有效、可及的临床解决方案,以满足大量尚未被满足的临床需求。主营业务收入 构成为：销售商品99.46%，出售材料0.38%，租赁服务0.16%。 荣昌生物所属申万行业为： ...

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board 100 Index decreased by 0.34% as of December 1, 2025, with mixed performance among constituent stocks [1] - Lexin Technology led the gains with an increase of 8.3%, while Dongxin Co., Ltd. experienced the largest decline at 7.3% [1] - The Sci-Tech 100 ETF (588800) saw a trading volume of 2.43 billion yuan, with a turnover rate of 9.69% [1] Group 2 - The Sci-Tech Semiconductor Materials and Equipment Theme Index rose by 0.26%, with Huahai Chengke up by 7.34% [1] - The Sci-Tech Semiconductor ETF (588170) increased by 0.14%, with a latest price of 1.39 yuan [1] - Yushu Technology's IPO guidance status has been updated to "guidance work completed," indicating readiness for IPO application [1] Group 3 - Dongwu Securities predicts a potential surge in the robotics sector in December, driven by deep adjustments and catalysts such as Tesla's third-generation release and Yushu's IPO application [2] - The Sci-Tech 100 ETF (588800) tracks the Sci-Tech 100 Index, focusing on high-growth sectors including semiconductors, pharmaceuticals, and new energy [2] - The Sci-Tech Semiconductor ETF (588170) encompasses companies in semiconductor equipment (61%) and materials (23%), benefiting from domestic substitution trends and AI-driven demand [2]

Group 1 - BlackRock reduced its stake in Rongchang Biologics (09995) by 185,500 shares at a price of HKD 81.6411 per share, totaling approximately HKD 15.1444 million [1] - After the reduction, BlackRock's latest shareholding stands at approximately 10.411 million shares, representing a holding percentage of 4.99% [1]

Group 1 - BlackRock reduced its stake in Rongchang Biologics (09995) by 185,500 shares at a price of HKD 81.6411 per share, totaling approximately HKD 15.1444 million [1] - After the reduction, BlackRock's remaining shareholding is approximately 10.4111 million shares, representing a stake of 4.99% [1]

Core Insights - The biopharmaceutical sector experienced a slight increase of 0.09% on November 28, with Rongchang Biopharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] Biopharmaceutical Sector Performance - Rongchang Biopharmaceutical (688331) closed at 99.70, with a rise of 3.85% and a trading volume of 71,200 shares, amounting to a transaction value of 708 million yuan [1] - Wanzhe Co., Ltd. (000534) saw a closing price of 20.53, increasing by 2.80% with a trading volume of 121,900 shares, totaling 248 million yuan [1] - Kanghua Biopharmaceutical (300841) closed at 81.81, up 2.10%, with a trading volume of 25,700 shares and a transaction value of 208 million yuan [1] - Other notable performers included Nearshore Protein (688137) at 42.25 (+1.81%), and Wofoo Biopharmaceutical (300357) at 31.49 (+1.68%) [1] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 533 million yuan from institutional investors, while retail investors contributed a net inflow of 300 million yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Kanghong Pharmaceutical (002773) experienced a net inflow of 4.21 million yuan from institutional investors, while it faced a net outflow of 4.38 million yuan from speculative funds [3] - Notable net inflows from retail investors were observed in stocks like Nuozhilan (920047) with 2.51 million yuan, while stocks like Baik Biopharmaceutical (688276) faced net outflows from retail investors [3]

Market Overview - The biopharmaceutical sector experienced a decline of 0.52% on November 27, with Sangfor Biopharma leading the drop [1] - The Shanghai Composite Index closed at 3875.26, up 0.29%, while the Shenzhen Component Index closed at 12875.19, down 0.25% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Olin Biotech (688319) with a closing price of 25.49, up 4.98% and a trading volume of 103,300 shares, totaling 263 million yuan [1] - Rongchang Biopharma (688331) closed at 96.00, up 4.07% with a trading volume of 65,600 shares, totaling 623 million yuan [1] - Hualan Biological (301207) closed at 24.70, up 2.57% with a trading volume of 222,400 shares, totaling 538 million yuan [1] - Conversely, significant decliners included: - Sangfor Biopharma (688336) closed at 64.70, down 5.40% with a trading volume of 60,400 shares, totaling 400 million yuan [2] - Jindike (688670) closed at 29.32, down 5.11% with a trading volume of 155,900 shares, totaling 453 million yuan [2] - WanTai Biotech (603392) closed at 49.09, down 2.89% with a trading volume of 52,600 shares, totaling 260 million yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 251 million yuan from institutional investors, while retail investors experienced a net inflow of 229 million yuan [2] - Notable capital flows included: - Rongchang Biopharma had a net inflow of 64.13 million yuan from institutional investors, while retail investors saw a net outflow of 39.11 million yuan [3] - Olin Biotech experienced a net inflow of 7.37 million yuan from institutional investors, with retail investors facing a net outflow of 24.86 million yuan [3]